title: Carotid artery atherosclerosis: what is the evidence for drug action?
abstract: Carotid artery disease is a well-established cause of cerebrovascular events. This risk is predicted by the severity of stenosis and other plaque characteristics that can be documented using imaging techniques. Among these techniques, ultrasound is the most widely available. Increased carotid intima-media thickness (IMT) measured ultrasonically is associated with a higher risk for cerebrovascular as well as coronary heart disease. Furthermore, it is increasingly recognized that echolucent and heterogeneous carotid plaques in patients with high-grade carotid stenosis are associated with a greater risk for cerebrovascular events. Several local and systemic factors can influence plaque stability. Identifying the high-risk carotid plaque could improve selection for vascular intervention (surgery/angioplasty) and increase cost-effectiveness. Aggressive medical treatment should always be provided for these high-risk patients. For example, lipid-lowering, anthihypertensive and antiplatelet drugs decrease the carotid IMT, stabilize carotid plaques or reduce the risk of cerebrovascular and systemic events. Continuously evolving technology will lead to more accurate identification of high-risk carotid plaques. A combination of comprehensive non- or minimally-invasive imaging techniques together with measuring clinical and systemic biochemical markers of risk may facilitate the identification of the vulnerable plaque in the vulnerable patient, and help select the best treatment options.
authors: Department of Medicine, Division of Clinical Epidemiology, McGill University, Montreal, QC, Canada. stella.daskalopoulou@clinepi.mcgill.ca
authors: Stella S
authors: SS
authors: Daskalopoulou
authors: Marios E
authors: ME
authors: Daskalopoulos
authors: Despina
authors: D
authors: Perrea
authors: Andrew N
authors: AN
authors: Nicolaides
authors: Christos D
authors: CD
authors: Liapis
mesh_terms: D000818:Animals; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D002340:Carotid Artery Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019317:Evidence-Based Medicine; D006801:Humans; D000960:Hypolipidemic Agents / Q000627:therapeutic use*
chemical_list: D000959:Antihypertensive Agents; D000960:Hypolipidemic Agents